COVID-19 rapid guideline: managing COVID-19

What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

What risk factors in people who are critically ill and have, or have had, COVID-19 as part of their acute illness are associated with developing COVID-19-associated pulmonary aspergillosis (CAPA)?

What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most accurate tests for diagnosing the infection and when should they be done?

What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:
• available tests for diagnosing CAPA
• available treatments for CAPA?

What are the clinical and cost effectiveness, and the safety, of specific antifungal treatments for treating suspected or confirmed COVID-19-associated pulmonary aspergillosis (CAPA), and the optimal treatment duration? When should treatment be started, stopped or modified?

What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

Does early review and referral to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their life?

Is high-flow nasal oxygen effective in reducing breathlessness compared with standard care or conventional oxygen therapy for people in hospital with COVID-19 and respiratory failure when it is agreed that treatment will not be escalated beyond non-invasive respiratory support or palliative care is needed?

Does a multidisciplinary team agreed approach to weaning from continuous positive airway pressure improve weaning times and result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure?

What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?

What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?